In contrast, the second key study [19] described ELF3 as an oncogenic driver of PCa, based on the detection of high levels of ELF3 mRNA in patient data sets and elevated expression of ELF3 protein in 63% of 207 tumours. The gene discussed is ELF3; the disease is posterior cortical atrophy.